

ASX Announcement

onCARlytics and Artemis® T cells combination presented as part of abstract at American Society of Gene and Cell Therapy's Annual Meeting

Sydney, Australia, 3 May 2023: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce its onCARlytics technology, in combination with Eureka Therapeutics' Artemis® T cell platform, has been presented as part of an abstract at the American Society of Gene and Cell Therapy's Annual Meeting (ASGCT).

The abstract, titled 'Effective combination immunotherapy using onCARlytics and Artemis® CD19 T cells against hepatocellular carcinoma', investigates the combination in the most primary type of liver cancer and sixth most common cancer worldwide.

While hepatocellular carcinoma (HCC) has systemic therapies and curative treatment options, CD19 targeting CAR T cell therapy has shown positive clinical outcomes, despite some ongoing challenges in bringing effective results into solid cancers.

The abstract presented at ASGCT noted that the combination of onCARlytics and Artemis® CD19 T cells demonstrated impressive in vivo anti-tumour responses in a human xenograft HepG2 model. It also stated that the combination strategy can be applied to otherwise target-less tumours such as HCC, and this shows the potential this could be applicable to a wide array of solid cancers as an effective immunotherapy approach.

The ASGCT event is now in its 26th year and attracts a range of professionals in the area of gene and cell therapy, who observe new scientific research and technologies alongside peers in the industry. It is being held 16–20 May 2023 at the Los Angeles Convention Center, CA, USA.

The full abstract can be viewed at: <https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=14786>



For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
View us on YouTube @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing



body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer